Cyclacel Pharmaceuticals, Inc..
CYCC.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel, mechanism-based drugs to treat human cancers and other serious diseases. The company focuses on developing treatments that target fundamental aspects of cell cycle c...Show More
Better Health for All
20
Cyclacel Pharmaceuticals' core business is dedicated to the discovery, development, and commercialization of novel drugs to treat human cancers and other serious diseases, indicating its entire business is devoted to health improvement.
1
Interim Phase 2 clinical data for fadraciclib showed potential efficacy in advanced solid tumors, with two patients achieving stable disease and one showing tumor shrinkage.
2
A study on plogosertib demonstrated it reduces fibrolamellar hepatocellular carcinoma (FLC) growth in patient-derived models, and FLC is a rare liver cancer with no approved treatments.
3
The company has no revenue from products with established negative health outcomes.
4
Regarding safety, initial Phase 1 data for plogosertib indicated it was well-tolerated with no dose-limiting toxicity.
5
Fadraciclib was also well-tolerated in a Phase 2 study, with no Grade 3 or higher treatment-emergent adverse events reported.
6
Fair Money & Economic Opportunity
0
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing cancer treatments. The ethical value 'Fair Money & Economic Opportunity' assesses activities related to lending, insuring, moving, or storing money. As a biopharmaceutical company, its core business does not involve financial services or products. The provided articles discuss other entities (Geron Corporation and Scottish Enterprise) and do not contain any evidence pertaining to CYCC.US's involvement in financial activities.
1
Therefore, all KPIs under this value are scored as '0' because they are not applicable to the company's operations.
Fair Pay & Worker Respect
-30
Cyclacel Pharmaceuticals, Inc. announced a reduction of 28 jobs in 2008, which represented 34% of its total staff, leading to the closure of its Cambridge, UK research facility.
1
The company incurred an estimated $0.5 million charge for severance payments in Q3 2008.
2
On Glassdoor, the company has an overall employee rating of 4.0 out of 5.0, a culture rating of 4.0, and a work-life balance rating of 3.0.
3
The CEO approval rating is 100%.
4
The CEO's employment agreement includes medical, dental, and life insurance benefits, with continuation of medical coverage under specific termination scenarios.
5
Fair Trade & Ethical Sourcing
0
No specific, quantitative data relevant to fair trade and ethical sourcing metrics, such as fair-trade certification share, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, was found in the provided articles.
1
Honest & Fair Business
0
No evidence available to assess Cyclacel Pharmaceuticals, Inc. on Honest & Fair Business.
Kind to Animals
20
Cyclacel Pharmaceuticals, Inc. used 31 NSG mice for in vivo analyses in a study involving CP253C CRPC PDX models.
1
The company also employs non-animal methods such as cell lines, patient-derived xenograft organoids, and mouse prostate cancer organoids as models in its research.
2
No War, No Weapons
0
The company develops cancer medicines, specifically fadraciclib and CYC140, which are described as a CDK2/9 inhibitor and a PLK1 inhibitor, respectively.
1
No information suggests these products have dual-use applications.
2
Planet-Friendly Business
0
No specific, quantitative data points related to environmental performance, emissions, renewable energy, water use, waste, certifications, or climate-related targets and disclosures were found in the provided articles. The articles primarily focus on corporate governance
1
or explicitly state the absence of relevant ESG metrics, thus no KPIs can be scored.
2
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'. The articles primarily focus on clinical trial data for drug candidates or corporate governance, and do not contain information regarding community engagement, cultural impact, or related policies.
1
Safe & Smart Tech
0
No specific, concrete data points or metrics relevant to the 'Safe & Smart Tech' ethical value for CYCC.US were found across the provided articles. The articles either contained no relevant information, were general industry discussions without company-specific data, focused on corporate governance without security or privacy metrics, or could not be accessed due to technical issues.
Zero Waste & Sustainable Products
0
The provided article details EPA regulations for managing hazardous waste pharmaceuticals and does not contain any specific information, data, or initiatives related to CYCC.US's waste management practices, product design, packaging, or any other aspect relevant to the Zero Waste & Sustainable Products value.
1